Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline

CAMBRIDGE, Mass. and SOMERSET, N.J (PRWEB) July 29, 2020 Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies,…

Source link

Related posts

Fight Aging! Newsletter, April 8th 2019


AtTRAPPC11/ROG2: A Role for TRAPPs in Maintenance of the Plant Trans-Golgi Network/Early Endosome Organization and Function


How to make kefir more healthful using sound


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World